Q2 2026 Kuros Biosciences AG Earnings Call

August 13, 2026

Operator: Good day and thank you for standing by. Welcome to the Kuros Biosciences H1 2026 conference call and webcast. I will now hand over to Carly Dahmer, Vice President, Marketing. Please go ahead.

Operator: Good day and thank you for standing by. Welcome to the Kuros Biosciences H1 2026 conference call and webcast. I will now hand over to Carly Dummer, Vice President, Marketing. Please go ahead.

Speaker #1: Good day, and thank you for standing by. Welcome to the Kuros Bioscience half-year results 2026 conference call and webcast. I will now hand over to Carly Dahmer, Vice President Marketing.

Speaker #1: Please go ahead.

Carly Dahmer: Thank you. Good morning, everybody, and welcome to the half-year financial results webcast. With me today and presenting to you will be Chris Fair, our CEO, and Daniel Geiger, our CFO. The presentation today will be followed by a Q&A, so please submit your questions via the webcast and I will run that session at the end. A quick reminder that the press release, the webcast deck, and the annual report are available on our website. We will scroll to the disclaimers, which are also available for download if you would like to read in detail. With that, I will hand over to Chris.

Carly Dummer: Thank you. Good morning, everybody, and welcome to the half-year financial results webcast. With me today and presenting to you will be Chris Fair, our CEO, and Daniel Geiger, our CFO. The presentation today will be followed by a Q&A, so please submit your questions via the webcast and I will run that session at the end. A quick reminder that the press release, the webcast deck, and the annual report are available on our website. We will scroll to the disclaimers, which are also available for download if you would like to read in detail. With that, I will hand over to Chris.

Speaker #2: Thank you. Good morning, everybody, and welcome to the half-year financial results webcast. With me today and presenting to you will be Chris Fair, our CEO, and Daniel Geiger, our CFO.

Speaker #2: The presentation today will be followed by Q&A, so please submit your questions via the webcast, and I will run that session at the end.

Speaker #2: A quick reminder that the press release, the webcast deck, and the annual report are available on our website. We will now scroll to the disclaimers, which are also available for download if you'd like to read them in detail.

Speaker #2: With that, I will hand over to Chris.

Chris Fair: Thanks, Carly. Good morning and good afternoon from wherever you are located. Starting with the H1 2026, Kuros has reached an important inflection point. We delivered $92.4 million in total medical device sales, representing a 45% growth compared to the H1 2025. This continues to demonstrate a strong adoption of our core technology platform. Just as importantly, this growth is now translating into profitability. We delivered $12.5 million in adjusted EBITDA, representing a 13.6% adjusted EBITDA margin and generated $4.4 million in net profit for the period. This is a meaningful milestone for Kuros as we are no longer simply a high-growth company. We are now a profitable, high-growth medical technology company with a strong commercial engine, a debt-free balance sheet, and continued investment capacity to support our long-term growth ambitions.

Speaker #3: Thanks, Carly. Good morning and good afternoon from wherever you're located. Starting with the first half of 2026, Kuros has reached an important inflection point.

Speaker #3: We delivered 92.4 million dollars in total medical device sales, representing a 45% growth compared to the first half of 2025. This continues to demonstrate a strong adoption of our core technology platform, but just as importantly, this growth is now translating into profitability.

Speaker #3: We delivered 12.5 million dollars in adjusted EBITDA, representing a 13.6% adjusted EBITDA margin, and generated 4.4 million dollars in net profit for the period.

Speaker #3: This is a meaningful milestone for Kuros, as we are no longer simply a high-growth company. We're now a profitable, high-growth medical technology company with a strong commercial engine, a debt-free balance sheet, and continued investment capacity to support our long-term growth ambitions.

Chris Fair: The charts on this slide show the consistency of our revenue growth, the acceleration of quarterly sales, and the important shift into positive net profit. This is the story we want our investors to understand. That growth is strong, profitability is emerging, and the foundation of this business is becoming increasingly robust. Next slide, please. Our growth is supported by three reinforcing pillars: expanding commercial reach, leadership in evidence generation, and operational scale. First, commercially, we continue to see strong growth in all areas in extremities, including foot and ankle and trauma. We are also seeing increasing adoption of MagnetOs in spine. Our expanded formulations, including MIS, Flex Matrix, are helping us address a broader range of surgeon needs and procedural preferences. Secondly, evidence remains a key differentiator for Kuros. We have three level 1 studies underway with enrollment on track designed to further demonstrate our performance compared with other key competitors.

Speaker #3: The charts on this slide show the consistency of our revenue growth, the acceleration of quarterly sales, and the important shift into positive net profit.

Speaker #3: This is the story we want our investors to understand: that growth is strong, profitability is emerging, and the foundation of this business is becoming increasingly robust.

Speaker #3: Next slide, please. Our growth is supported by three reinforcing pillars. Expanding commercial reach, leadership and evidence generation, and operational scale. First, commercially, we continue to see strong growth in all areas and extremities, including foot and ankle and trauma, while also seeing increasing adoption of many tests and spine.

Chris Fair: We are also seeing increasing adoption of MagnetOs in spine. Our expanded formulations, including MIS, Flex Matrix, are helping us address a broader range of surgeon needs and procedural preferences. Secondly, evidence remains a key differentiator for Kuros. We have three level 1 studies underway with enrollment on track designed to further demonstrate our performance compared with other key competitors.

Speaker #3: Our expanded formulations include the MIS, Flex Matrix, are helping us address a broader range of surgeon needs and procedural preferences. Secondly, evidence remains a key differentiator for Kuros.

Speaker #3: We have three level one studies underway with enrollment on track, designed to further demonstrate our performance compared with other key competitors. We also recently published new clinical evidence that reinforces fusion speed and high-risk patients and supports the use in cervical procedures.

Chris Fair: We also recently published new clinical evidence that reinforces fusion speed in high-risk patients and supports the use in cervical procedures. Third, operationally, we are scaling the platform. We continue to invest in our manufacturing capacity, digital infrastructure, and organizational capabilities. Our US facility is expected to go live in the H2 of this year, and the next phase of the Netherlands expansion is also expected to be complete in the same time period. Taken together, these initiatives position us to serve a larger market opportunity while building a more resilient, scalable, and efficient business. Next slide, please. As we are growing the business, we are expanding our distribution reach, deepening hospital penetration, and accelerating surgeon adoption. We do this and continue to gain market share. In the H1 of 2026, we saw a 34% growth in our distributor reach compared to the H1 of 2025.

Speaker #3: Third, operationally, we are scaling the platform. We continue to invest in our manufacturing capacity, digital infrastructure, and organizational capabilities. Our US facility is expected to arrive in the second half of this year, and the next phase of the Netherlands expansion is also expected to be complete in the same time period.

Speaker #3: Taken together, these initiatives position us to serve a larger market opportunity while building a more resilient, scalable, and efficient business. Next slide, please. As we are growing the business, we are expanding our distribution reach, deepening hospital penetration, and accelerating surgeon adoption.

Speaker #3: We do this in continued to gain market share. And the first half of 2026, we saw a 34% growth in our distributor reach compared to the first half of 2025.

Chris Fair: Hospital account growth has also remained very strong, and surgeon utilization continues to increase as a growing share of US spine surgeons choose us. The key point here is that growth is not dependent upon one single lever. It is being driven by broader commercial platform, more distributors, more hospital access, more surgeons using the product, stronger institutional relationships through our IDN contracts, and broader channel access. We estimate that our market share has increased approximately fourfold since 2023, which reflects, again, a continued adoption and the effectiveness of our commercial strategy. For our investors, the takeaway is straightforward. Kuros is strengthening its position in the market through expanded adoption and deeper partnerships and broader access. Next slide, please. Our addressable market remains large and growing. The global orthopedic biomaterial market is expected to grow from approximately $5.5 billion in 2025 to $8.2 billion in 2032.

Speaker #3: Hospital account growth has also remained very strong, and surgeon utilization continues to increase as a growing share of U.S. spine surgeons choose us. The key point here is that growth is not dependent upon one single lever.

Speaker #3: It is being driven by a broader commercial platform, more distributors, increased hospital access, more surgeons using the product, stronger institutional relationships through our IDN contracts, and broader channel access.

Speaker #3: We estimate that our market share has increased approximately fourfold since 2023, which reflects, again, a continued adoption and the effectiveness of our commercial strategy.

Speaker #3: For our investors to take away a straightforward. Kuros is strengthening its position in the market through expanded adoption, and deeper partnerships, and broader access.

Speaker #3: Next slide, please. Our addressable market remains large and growing. The global orthopedic biomaterial market is expected to grow from approximately $5.5 billion in 2025 to $8.2 billion in 2032.

Chris Fair: Spine still remains the largest current market opportunity, but we also see attractive opportunities, obviously, in foot and ankle, trauma, and other adjacent applications. Our strategy is to continue building from our strength in spine while expanding into additional segments where biologics remain under-penetrated and where evidence can create meaningful differentiation. In spine, we are focused on a targeted engagement, evidence generation, and a disciplined sales approach. In foot and ankle trauma, we are one of the few companies specifically focused on biologics in this space, but also providing a level 1 evidence generation. Today, more than 150,000 patients worldwide have been treated with MagnetOs since our launch. This gives us a strong base from which to expand. We are not just entering new markets, we are building the clinical, commercial, and operational capabilities required to maximize reach over time. Next slide, please. We currently have three very important studies underway.

Speaker #3: Spine still remains the largest current market opportunity, but we also see attractive opportunities, obviously, in foot and ankle, trauma, and other adjacent applications. Our strategy is to continue to build in from our strength in spine while expanding into additional segments where biologics remain under-penetrated and where evidence can create meaningful differentiation.

Chris Fair: In spine, we are focused on a targeted engagement, evidence generation, and a disciplined sales approach. In foot and ankle trauma, we are one of the few companies specifically focused on biologics in this space, but also providing a level 1 evidence generation. Today, more than 150,000 patients worldwide have been treated with MagnetOs since our launch. This gives us a strong base from which to expand. We are not just entering new markets, we are building the clinical, commercial, and operational capabilities required to maximize reach over time. Next slide, please. We currently have three very important studies underway.

Speaker #3: In spine, we're focused on targeted engagement, evidence generation, a few, and a discipline sales approach. In foot and ankle, trauma, we're one of the few companies specifically focused on biologics in this space, but also providing level one evidence generation.

Speaker #3: And today, more than 150,000 patients worldwide have been treated with Magnetos since our launch. This gives us a strong base from which to expand, we're not just entering new markets, we are building the clinical, commercial, and operational capabilities required to maximize reach over time.

Speaker #3: Next slide, please. We currently have three very important studies underway: PROOF is evaluating easy pack putty versus DBM or fibers in a posterolateral fusion, PRECISE is evaluating Flex Matrix versus Trinity Elite, and a posterolateral fusion, and ASTRA, the foot and ankle study, is looking at autograft versus autograft and hindfoot and ankle fusion.

Chris Fair: PROOF is evaluating Easypack Putty versus DBM or fibers in a posterior lateral fusion. PRECISE is evaluating Flex Matrix versus Trinity Elite in a posterior lateral fusion. ASTRA, the foot and ankle study, is looking at versus autograft in the hind foot and ankle fusion. The enrollment progress is encouraging. PROOF is at 83%, PRECISE 49%, and ASTRA at 14%. The active sites are supporting each of these studies, and we engage more and more each day. The importance of these programs goes beyond the individual trials. Together, these studies are designed to strengthen the evidence base for us across spine and extremities, support surgeon confidence, and help Kuros continue to differentiate itself in a competitive marketplace. In short, we are investing in the type of rigorous clinical evidence that surgeons, hospitals, importantly, payers, increasingly expect. Next slide, please. This slide addresses a practical and important question for surgeons.

Speaker #3: The enrollment progress is encouraging. PROOF is at 83%, PRECISE 49%, and ASTRA at 14%. And the active sites are supporting each of these studies, and we engage more and more each day.

Speaker #3: The importance of these programs goes beyond the individual trials. Together, these studies are designed to strengthen the evidence base for us across spine and extremities, support surgeon confidence, and help Kuros continue to differentiate itself in a competitive marketplace.

Speaker #3: In short, we're investing in the type of rigorous clinical evidence that surgeons, hospitals, importantly, payers increasingly expect. Next slide, please. This slide addresses a practical and important question for surgeons.

Chris Fair: How can we be confident in our fusion? Our ability is to build evidence across multiple levels. We start with bench-top data, including surface science, material characterization. Then we build on that with preclinical animal data, including histological evidence and bone formation. We do not stop there, like many companies do. From there, we move into human clinical data using imaging such as X-ray, CT, and 3D reconstruction. Now with surgical exploration biopsy initiative, we are adding a human histological and visual confirmation of bone formation. No other company is doing this. This is important because it helps demonstrate that not only that fusion occurs, but also how and where new bone forms. For Kuros, this evidence portfolio is a strategic asset. It supports surgeon confidence, strengthens our scientific positioning, and reinforces the differentiated mechanism and performance profile of MagnetOs. Next slide.

Speaker #3: How can we be confident in our fusion? Our ability is to build evidence across multiple levels. We start with benchtop data, including surface science, material characterization, then we build on that with preclinical animal data, including histological evidence of bone formation.

Speaker #3: We don't stop there, like many companies do. From there, we move into human clinical data, using imaging such as X-rays, CT, and 3D reconstruction.

Speaker #3: And now, with surgical exploration and biopsy initiative, we're adding a human histological and visual confirmation of bone formation. No other company is doing this. This is important because it helps demonstrate not only that fusion occurs, but also how and where new bone forms.

Speaker #3: For Kuros, this evidence portfolio is a strategic asset. It supports surgeon confidence, strengthens our scientific positioning, and reinforces the differentiated mechanism and performance profile of Magnetos.

Speaker #3: Next slide. This is a recently published peer-reviewed study. And another important addition to our clinical evidence portfolio. The study retrospectively evaluated high-risk patients treated with Magnetos at six months following one to four-level anterior cervical discectomy and fusion, or an ACDF.

Chris Fair: This is a recently published peer-reviewed study and another important addition to our clinical evidence portfolio. The study retrospectively evaluated high-risk patients treated with MagnetOs at 6 months following one to four-level anterior cervical discectomy and fusion or an ACDF. The patient population was clinically challenging, with 63% of the patients having three or more comorbidities. Despite that high-risk profile, the study reported a 97.7% 6-month fusion rate assessed by CT. That is a clinically relevant early time point for spine surgeons, an important data point for MagnetOs. The study also expands our clinical evidence portfolio into the cervical indication and supports the broader use of MagnetOs Easypack Putty procedures for early confidence in fusions is highly valuable. The broader message is that our evidence base continues to grow, is increasingly relevant in real-world high-risk patient populations.

Speaker #3: The patient population was clinically challenging, with 63% of the patients having three or more comorbidities. Despite that high-risk profile, the study reported a 97.7% six-month fusion rate assessed by CT.

Speaker #3: That is a clinically relevant early time point for spine surgeons and important data point for Magnetos. The study also expands our clinical evidence portfolio into the cervical indication and supports the broader use of Magnetos easy pack putty and procedures for early confidence in fusion is highly valuable.

Speaker #3: The broader messages that our evidence base continues to grow is increasingly relevant in real-world high-risk patient populations. And with that, clinical and commercial foundation in place, we can now turn to the financial model and how revenue scale has translated into operating leverage and profitability.

Chris Fair: With that clinical and commercial foundation in place, we can now turn to the financial model and how revenue scale is translating into operating leverage and profitability. With that, I will turn it over to Daniel.

Speaker #3: And with that, I'll turn it over to Daniel.

Daniel Geiger: Thank you, Chris. H1 was another strong period for Kuros. Medical device revenue reached $92.4 million, up 45% year-on-year. Direct MagnetOs sales grew 46%, continuing the strong momentum we have seen over the past periods. Importantly, this growth is not price-driven. It reflects continued market penetration, segment expansion, and mix with pricing discipline maintained in competitive market. The P&L is also scaling well. Since H1 2023, revenue has grown by around 566%, while fixed cost increased by around 271%. That is a clear indication of operating leverage coming through the model. We reached an important inflection point. We delivered, for the first-ever time, a half-year profitability. Adjusted EBITDA was at CHF 12.5 million, representing a 13.6% margin. Net profit arrived at CHF 4.4 million. Gross margin remained robust as we scaled. This reflects volume growth, continued unit cost optimization, supply chain productivity, and tariff mitigation.

Speaker #2: Thank you, Chris. H1 was another strong period for Kuros. Medical device revenue reached 92.4 million, up 45% year on year. Direct Magnetos sales grew 46%, continuing the strong momentum we have seen over the past periods.

Speaker #2: Importantly, this growth is not price-driven. It reflects continued market penetration segment expansion and mix with pricing, discipline, maintained in competitive market. The P&L is also scaling well.

Speaker #2: Since H1 23, revenue has grown by around 566%, while fixed cost increased by around 271%. That is a clear indication of operating leverage coming through the model.

Speaker #2: And we reached an important inflection point. We delivered, for the first time ever, half-year profitability. Adjusted EBITDA was CHF 12.5 million, representing a 13.6% margin. Net profit arrived at CHF 4.4 million.

Speaker #2: Gross margin remained robust as we scaled. This reflects volume growth, continued unit cost optimization, supply chain productivity, and tariff mitigation. On the sales and marketing, we continue to invest with discipline.

Daniel Geiger: On the sales and marketing, we continue to invest with discipline. Spend is targeted to areas where we see clear return while also building the early capabilities needed for the trauma opportunity. R&D remains focused and targeted. The priority continues to be evidence generation, line extension, and selected new product development. Our main evidence programs, PROOF, PRECISE, and ASTRA, remain on track as outlined by Chris Fair. At the same time, we continue to support targeted innovation with a cost base that can scale with the business. With regards to G&A, we expensed on top around CHF 2 million of business transformation cost. These relate mainly to product engineers, operators, IT experts, and selected IT applications that were not capitalized. While there is a temporary impact on G&A, this is a deliberate investment in the platform. It strengthens the system infrastructure and capabilities we need to scale efficiently.

Speaker #2: Spend is targeted to areas where we see clear return while also building the early capabilities needed for the trauma opportunity. R&D remains focused and targeted.

Speaker #2: The priority continues to be evidence generation, line extension, and selected new product development. Our main evidence programs PROOF, PRECISE, and ASTRA remain on track as outlined by Chris.

Speaker #2: At the same time, we continue to support targeted innovation with a cost base that can scale with the business. With regards to G&A, we expand on top around 2 million of business transformation cost.

Speaker #2: These relate mainly to product engineers, operators, IT experts, and selected IT applications that were not capitalized. So while there is a temporary impact on G&A, this is a deliberate investment in the platform.

Speaker #2: It strengthens the system infrastructure and capabilities we need to scale efficiently. The key enablers are automation, digitization, and the global MRP backbone. Adjusted EBITDA was $12.5 million, or a 13.6% margin.

Daniel Geiger: The key enablers are automation, digitization, and the global MRP backbone. Adjusted EBITDA was CHF 12.5 million, or a 13.6% margin. This is in absolute terms 60% versus H1 2025 up, compared with revenue growth of 45%. We also delivered CHF 4.4 million of net profit compared with a CHF 2 million loss last year. That marks a meaningful profitability inflection point for the business. EPS improved from a loss of 5 cents to earnings of 11 cents. For the first time, the earnings power of the platform is clearly visible in the reported numbers. We closed June with CHF 9.7 million in cash and CHF 44.4 million in receivables. Combined, that represents CHF 54.2 million of cash and receivables. We remain debt-free with strong operating cash flow and the undrawn CHF 12.4 million bridge facility available if needed. The working capital build is deliberate and growth-linked. Inventory supports second half demand and the US production ramp.

Speaker #2: This is an absolute terms 60% versus H1 25, up compared with revenue growth of 45%. We also delivered 4.4 million of net profit compared with a 2 million loss last year.

Speaker #2: That marks a meaningful profitability inflection point for the business. EPS improved from a loss of 5 cents to earnings of 11 cents. For the first time, the earnings power of the platform is clearly visible in the reported numbers.

Daniel Geiger: We closed June with CHF 9.7 million in cash and CHF 44.4 million in receivables. Combined, that represents CHF 54.2 million of cash and receivables. We remain debt-free with strong operating cash flow and the undrawn CHF 12.4 million bridge facility available if needed. The working capital build is deliberate and growth-linked. Inventory supports second half demand and the US production ramp.

Speaker #2: We closed June with 9.7 in cash and 44.4 million in receivables. Combined, that represents 54.2 million of cash and receivables. We remain debt-free with strong operating cash flow and an on-drawn 12.4 million bridge facility available if needed.

Speaker #2: The working capital build is deliberate and growth-linked. Inventory supports second-half demand and the US production ramp. Over time, we expect that net working capital to normalize to a single-digit percentage of sales.

Daniel Geiger: Over time, we expect that net working capital to normalize to a single-digit percentage of sales. CapEx remains focused on capacity and capability. Alpharetta and the Netherlands R&D and production center support dual sourcing, resilience, and future margin expansion. Overall, the organic plan remains funded through operating cash flow. The bridge facility is available as an additional liquidity backstop, but remains undrawn as of H1 2026. Looking ahead, we expect revenue to more than double from CHF 146 million in 2025 to CHF 300 million to CHF 330 million by 2028. For 2026, we expect growth of approximately 35%. The key drivers are continued adoption, broader access, line extension, selected new products, and international expansion. The margin bridge is built around four clear levers: unit cost optimization, commercial operating leverage, targeted R&D investments, G&A operational leverage. Together, these levers deliver more than 6 percentage points of improvement in functional cost ratios.

Speaker #2: Capex remains focused on capacity and capability. Alpharetta and the Netherlands R&D and production center support dual sourcing resilience and future margin expansion. Overall, the organic plan remains funded through operating cash flow.

Speaker #2: The bridge facility is available as an additional liquidity-backed stop, but remains on-drawn as of H1 26. Looking ahead, we expect revenue to more than double from 146 million in 25 to 300 to 330 million by 2028.

Daniel Geiger: Looking ahead, we expect revenue to more than double from CHF 146 million in 2025 to CHF 300 million to CHF 330 million by 2028. For 2026, we expect growth of approximately 35%. The key drivers are continued adoption, broader access, line extension, selected new products, and international expansion. The margin bridge is built around four clear levers: unit cost optimization, commercial operating leverage, targeted R&D investments, G&A operational leverage. Together, these levers deliver more than 6 percentage points of improvement in functional cost ratios.

Speaker #2: For 26, we expect growth of approximately 35%. The key drivers are continued adoption broader access, line extension, selected new products, and international expansion. The margin bridge is built around four clear levers: unit cost optimization, commercial operating leverage, targeted R&D investments, G&A operational leverage.

Speaker #2: Together, these levers deliver more than 6% points of improvement in functional cost ratios. That supports our path to an adjusted EBITDA margin above 20% by 2028.

Daniel Geiger: That supports our path to an adjusted EBITDA margin above 20% by 2028. The operating model is illustrative and aligned with our midterm guidance. The individual ratios are indicative and should not be read as separate guidance. Our formal guidance remains revenue of CHF 300 million to CHF 330 million and an adjusted EBITDA margin of above 20% by 2028. With that, I hand back to Chris Fair. Thank you.

Speaker #2: The operating model is illustrative, and aligned with our mid-term guidance. The individual ratios are indicative and should not be read as separate guidance. Our formal guidance remains revenue of 300 to 330 million, and an adjusted EBITDA margin of above 20% by 2028.

Speaker #2: And with that, I hand back to Chris. Thank you.

Chris Fair: Later this year, as Daniel briefly mentioned, we expect to bring on the Alpharetta, Georgia, manufacturing facility. This creates a dual-source production platform alongside our existing facility in Bilthoven in the Netherlands. This investment is about more than just additional capacity. It strengthens our supply chain resilience, de-risks the business, improves flexibility in serving key US customers, and helps us position us for long-term growth. It also supports localized production, which can help improve fulfillment responsiveness, and also help mitigate tariff-related risks. As demand continues to grow, having manufacturing capability on both sides of the Atlantic provides an important competitive advantage. It gives us greater operational flexibility while supporting economies of scale as the business expands. In short, we are building the infrastructure today that we believe will support the next phase of our growth journey. Next slide, please.

Speaker #3: Later this year, as Daniel briefly mentioned, we expect to bring on the Alpharetta Georgia manufacturing facility. This creates a dual-source production platform alongside our existing facility in Bilthoven in the Netherlands.

Speaker #3: This investment is about more than just additional capacity. It strengthens our supply chain resilience, de-risks the business, improves flexibility in serving key US customers, and helps us position us for long-term growth.

Speaker #3: It also supports localized production, which can help improve fulfillment responsiveness and also help mitigate tariff-related risks. As demand continues to grow, having manufacturing capability on both sides of the Atlantic provides an important competitive advantage.

Speaker #3: It gives us greater operational flexibility while supporting economies of scale as the business expands. In short, we're building the infrastructure today that we believe will support the next phase of our growth journey.

Speaker #3: Next slide, please. You know, having discussed our recent performance, I'd like to step back and talk about where we're headed. Our vision is to become a trusted global leader in orthobiologics, providing reliable, clinically proven solutions for hospitals, surgeons, and our patients.

Chris Fair: Having discussed our recent performance, I would like to step back and talk about where we are headed. Our vision is to become a trusted global leader in orthobiologics, providing reliable, clinically proven solutions for hospitals, surgeons, and our patients that we serve. Our mission remains focused on discovering and developing and delivering innovative biologic technologies. With that, we see four strategic priorities driving value creation over the coming years. First, we will continue expanding the adoption of our core business by increasing surgeon utilization, broadening our hospital access, and driving for further penetration in spine. The MIS represents an important opportunity within this effort and something that has been very successful from its launch about a year ago. Secondly, we will extend the portfolio.

Speaker #3: That we serve. Our mission remains focused on discovering and developing and delivering innovative biologic technologies. And with that, we see four strategic priorities driving value creation over the coming years.

Speaker #3: First, we will continue expanding the adoption of our core business by increasing surgeon utilization, broadening our hospital access, and driving for further penetration in spine.

Speaker #3: The MIS represents an important opportunity within this effort and something that has been very, very successful from its launch about a year ago. Secondly, we will extend the portfolio.

Chris Fair: This includes advancing the MagnetOs platform and developing new technologies, moving into resorbable settable bone void fillers, and exploring additional osteopromotive technologies and other business development opportunities. We will also continue growing beyond spine. We see attractive opportunities within foot and ankle and trauma, as we have mentioned before. We also think we can expand to a greater extent in the international marketplace, where we can leverage our clinical evidence, commercial platform, technology expertise, and recently achieved MDR approvals. Finally, we can continue scaling the platform itself. Our investments in manufacturing, ERP, MRP systems, and digital infrastructure are designed to strengthen our operating leverage and convert revenue growth into expanding profitability over time. Collectively, these priorities represent our view beyond 2028 and provide a clear framework for sustainable, profitable growth. Next slide, please. Our innovation strategy is intentionally balanced between short, medium, and long-term opportunities.

Speaker #3: This includes advancing the magnetos platform and developing new technologies moving into resorbable settable bone void fillers and exploring additional osteopromotive technologies and other business development opportunities.

Speaker #3: We'll also continue growing beyond spine. We see attractive opportunities within foot and ankle and trauma, as we've mentioned before, and we also think we can expand to a greater extent in the international marketplace.

Speaker #3: Where we can leverage our clinical evidence, commercial platform, technology expertise, and recently achieved MDR approvals. Finally, we can continue to scaling the platform itself.

Speaker #3: Our investments in manufacturing, ERP, MRP systems, and digital infrastructure are designed to strengthen our operating leverage and convert revenue growth into expanding profitability over time.

Speaker #3: Collectively, these priorities represent our view beyond 2028 and provide a clear framework for sustainable profitable growth. Next slide, please. Our innovation strategy is intentionally balanced between short, medium, and long-term opportunities.

Chris Fair: In the very near term, as we have discussed, our focus is on product launches and line extensions, including the MagnetOs MIS Gen 2, new Flex Matrix sizes that will get us into new procedures, and our resorbable settable bone void filler program. These initiatives are designed to support commercial growth and expand procedural adoption over the next several years. In the medium term, we are looking for opportunities in developing a resorbable settable bone void filler that might be combined with antibiotics while continuing to advance additional organic development programs that can create new market opportunities, add TAM to the business. Long term, we are exploring future product initiatives, including osteopromotive platforms, settable dead space management solutions, and we are also looking at organic and inorganic opportunities that can help broaden the scope of our technology platform. The key message is that Kuros is not relying on a single product or a single growth driver.

Speaker #3: You know, in the very near term, as we've discussed, our focus is on product launches and line extensions including the MIS Gen 2, new flex matrix sizes, that will get us into new procedures, and our resorbable settable bone void filler program.

Speaker #3: These initiatives are designed to support commercial growth and expand procedural adoption over the next several years. In the medium term, we're looking for opportunities in developing resorbable with settable bone void filler that might be combined with antibiotics.

Speaker #3: While continuing to advance additional organic development programs that can create new market opportunities add TAM to the business. Long term, we're exploring future product initiatives including osteopromotive platforms, you know, settable dead space management solutions, and we're also looking at organic and inorganic opportunities that can help broaden the scope of our technology platform.

Chris Fair: Long term, we are exploring future product initiatives, including osteopromotive platforms, settable dead space management solutions, and we are also looking at organic and inorganic opportunities that can help broaden the scope of our technology platform. The key message is that Kuros is not relying on a single product or a single growth driver.

Speaker #3: The key message is that CURIS is not relying on a single product or a single growth driver. We are building a disciplined, innovation pipeline that balances near-term revenue opportunities with longer-term strategic value creation.

Chris Fair: We are building a disciplined innovation pipeline that balances near-term revenue opportunities with longer-term strategic value creation. This approach allows us to continue strengthening the core business while building the foundation for growth well beyond our current planning horizon. Overall, we are very pleased, next slide, with our H1 performance. We delivered strong growth, achieved a meaningful profitability milestone. We continue to strengthen our clinical evidence leadership, and we have made significant progress on the infrastructure and innovation investments that support our long-term strategy. With that, I would like to thank our employees, our customers, our surgeons, our distributors, and importantly, our shareholders for their continued support. At this time, we would be happy to now take your questions.

Speaker #3: This approach allows us to continue strengthening the core business while building the foundation for growth well beyond our current planning horizon. Overall, we're very pleased. Next slide.

Speaker #3: With our first half performance, we delivered strong growth, achieved a meaningful profitability milestone, we continue to strengthen our clinical evidence leadership, and we've made significant progress on the infrastructure and innovation investments that support our long-term strategy.

Speaker #3: And so with that, I'd like to thank our employees, our customers, our surgeons, our distributors, and, importantly, our shareholders for their continued support. At this time, we'd be happy to take your questions.

Operator: Thank you. To ask a question, please press star 1 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 and 1 again. Once again, that is star 1 and 1 to ask a question. We will now take our first question. From the line of Laura Pfeifer from Octavian, please go ahead.

Speaker #1: Thank you. To ask a question, please press star 11 on your telephone and wait for your name to be announced. To wait for your question, please press star 1 and 1 again.

Speaker #1: Once again, that's star 1 and 1 to ask a question. We will now take our first question. From the line of Laura Pfeiffer from Octavian, please go ahead.

Laura Pfeifer-Rossi: Yes. Hello, everyone. Laura Pfeifer from Octavian here. Thanks for taking my questions. I have two of them. Maybe first on your sales growth, you had very strong 45% growth, but you kept the guidance unchanged at the level of, I understood it is at least 35%. I think, Daniel Geiger, you said around 35%. Anyway, I think it implies quite a moderation in H2 growth. Is there any specific reason that gives you more caution? Or how should we think about the level of confidence you have now, looking into Q3 and Q4? Then maybe the other question is on the margins. I think here you had a very good margin already in H1. I think it was 14% in the Q2 standalone, and this compares to your full year guidance of around 14%.

Speaker #2: Yes, hello. Everyone. Laura Pfeiffer from Octavian here. So thanks for taking my questions. I have two of them. I'm so maybe first on your sales growth, you had very strong 45% growth, but you kept the guidance unchanged of at the level of I understood it's at least 35%.

Speaker #2: I think Daniel said around 35%. But anyway, I think it implies quite a moderation in H2 growth. So is there any specific reason that gives you more caution or how should we think about the level of confidence you have now looking into Q3 and Q4?

Speaker #2: And then maybe the other question is on the margins. I think here you had a very good margin already in H1. I think it was 14% in the second quarter standalone.

Speaker #2: And this compares to your fully guidance of around 14%. So what are the principal positive and negative factors affecting the second half margin? And is it reasonable to assume that in the second half the profitability should be above the H1 level despite US manufacturing ramp-up?

Laura Pfeifer-Rossi: What are the principal positive and negative factors affecting the H2 margin? Is it reasonable to assume that in the H2, the profitability should be above the H1 level despite US manufacturing ramp up? Thank you.

Speaker #2: Thank you.

Chris Fair: I will take the first one, and Daniel can take the second one. I think, relative to updating guidance, from a general cadence perspective, that is something we tend to look at in the Q3 timeframe as we had last year. Right now we still see strong commercial adoption of the technology. We are not making any indications of a change in that pace. But again, from an updating of guidance perspective, that is something we look at from a corporate perspective in the Q3 timeframe if we are going to make adjustments. Daniel can address the second question.

Speaker #3: So I'll take the first one in data. If you take the second one, I think, you know, relative to updating guidance, you know, from a general cadence perspective, that is something we tend to look at in the third quarter timeframe as we had last year.

Speaker #3: So right now we still see, you know, strong commercial adoption of the technology. We're of a change in that pace. But again, from an updating of guidance perspective, that's something we look at from a corporate perspective in the Q3 timeframe if we're going to make adjustments.

Speaker #3: Daniel can address the second question.

Daniel Geiger: Yeah. With regards to the margin, I would almost say the same. We will give an update, obviously, on the guidance for top line as well as the margin in the second call for basically in Q3. What we can certainly observe right now is that the margins were slightly better than initially assumed. But there is still quite a lot of business transformation costs coming also in the Q3 and the Q4. Therefore, we will continue to watch this and then give an update once we have the visibility.

Speaker #4: Yeah, if we go to the margin, I would almost say the same. You know, we will give an update, obviously, on the guidance for top line as well as the margin in the second half, basically in Q3.

Speaker #4: I mean, what we can certainly observe right now is that, you know, the margins were slightly better than initially assumed. But, you know, there's still quite a lot of business transformation costs coming also in the third and the fourth quarter.

Speaker #4: And therefore, you know, we will continue to watch this and then give an update once we have the visibility.

Laura Pfeifer-Rossi: Okay. I think that is helpful. But just maybe specifically on the US manufacturing side, do you expect to have kind of dilutive effect, maybe at least in the initial phase? Or is this not material enough to have a really negative impact on margins in H2?

Speaker #2: Okay. I think that's helpful. But just maybe specifically on the US manufacturing side. So do you expect to have kind of dilutive effect maybe at least in the initial phase or is this not material enough to have a really negative impact on margins in H2?

Daniel Geiger: No, what we always said is that in order to ramp up the production that we need to have obviously operators shadowing and doing the tech transfer from the Netherlands to the US, that obviously will dilute to a certain extent. We try to ramp up the team in a way that it is smooth to the P&L. But that said, there will certainly be some dilutive effects. This is what we now always talked about also at the Capital Market Day, that we said 2026 is the year where we will invest into business transformation and should then further upside margin potential see 2027 and 2028.

Speaker #4: No, I mean, we always say this is that, you know, in order to ramp up the production that we need to have obviously operator shadowing and doing the tech transfer, right, from the Netherlands to the US.

Speaker #4: That obviously will dilute to a certain extent. We try to ramp up the team in a way that, you know, it's smooth to the P&L.

Speaker #4: But as said, I mean, there will certainly be some dilutive effects. I mean, this is what we now always talked about also at the capital market day that we said 2026 is the year where we will invest into business transformation.

Speaker #4: And should then further upside margin potential see 2027 and 2028.

Laura Pfeifer-Rossi: Okay, thanks. I jump back into the queue.

Speaker #2: Okay. Thanks. So I jump back into the queue.

Operator: Thank you. We will now take the next question from the line of Christian Ehmann from Berenberg. Please go ahead.

Speaker #1: Thank you. We will now take the next question. From the line of Christian Effman from Berenberg, please go ahead.

Christian Ehmann: Hey. Hello, everyone. Thanks for taking my question, guys. I am looking at the surgeon penetration rate. You showed us 16% in H2, H1, sorry. Can you talk a little bit about how you see the penetration rate or how you envision the penetration rate to grow in the future? Is it more surgeons or the existing surgeons more often using your product? Thank you.

Speaker #5: Hey, hello everyone. Thanks for taking my question, guys. I'm looking at the surgeon penetration rate. You showed us 16% in H2, H1, sorry. Can you talk a little bit about how you see the penetration rate or how you envision the penetration rate to grow in the future?

Speaker #5: Is it more surgeons, or the existing surgeons more often, using your product? Thank you.

Chris Fair: Thanks, Christian. I think what we see is it is a little bit of both. When we look at our business and we look at our spine surgeon foundation, we continue to see growth on the number of surgeons, but we have a higher penetration rate. What we are seeing with that surgeon group is greater depth with their procedure volumes. They may start using us in 10% or 20% of their cases, but once they see the results from that patient population, they will expand that throughout the rest of the practice. That is an evolution that we continue to see. When we look at our extremity physicians, that is a new foundational group of surgeons that we are just getting to know. That is a surgeon base that we are adding at a regular cadence at a very high rate.

Speaker #3: Thanks, Christian. I think what we see is it's a little bit of both, right? So when we look at our business and we look at our spine surgeon foundation, we continue to see growth in the number of surgeons, but we have a higher penetration rate.

Speaker #3: And so what we're seeing with that surgeon group is greater depth with their procedure volumes. So they may start using this in 10 or 20% of their cases, but once they see the results, from that patient population they'll expand that throughout the rest of the practice.

Speaker #3: So that's an evolution that we continue to see. When we look at the extremity physicians, that's a new foundational group of surgeons that we're just getting to know.

Speaker #3: And so that's a surgeon base that we are adding at a regular cadence at a very high rate. And so again, when you start thinking about early adopters versus the middle of the curve and the spine marketplace, we're approaching the middle part of the curve on penetration on the extremity side and trauma surgeons for the most part, we're in the early stage.

Chris Fair: When you start thinking about early adopters versus the middle of the curve, in the spine marketplace, we are approaching the middle part of the curve on penetration. On the extremity side and trauma surgeons, for the most part, we are in early stage. We are just getting to know that surgeon base. To the point earlier, we are not relying just on one lever. We have multiple levers that we are pulling from to grow our foundation.

Speaker #3: So we're just getting to know that surgeon base. So again, to the point earlier, we're not relying just on one lever. We have multiple levers that we're pulling from, you know, to grow our foundation.

Christian Ehmann: Thank you. Very helpful.

Chris Fair: Yeah.

Speaker #5: Thank you. Very helpful.

Operator: Thank you. There are no further questions on the phone at this time. I would like to hand back over for Apologies. There is one more question on the telephone. Coming from the line of Laura.

Speaker #1: Thank you. There are no further questions on the phone at this time. I would like to hand back over for apologies. There is one more question on the telephone.

Speaker #2: Yes, hi.

Laura Pfeifer-Rossi: Yes, hi.

Laura Pfeifer-Rossi: Rene from Octavian. Please go ahead.

Operator: Rene from Octavian. Please go ahead.

Speaker #1: Laura. Pfizer from Octavian, please go ahead.

Laura Pfeifer-Rossi: Yes. Hi. Just a follow-up. Maybe on the international sales, I saw that the number was quite lumpy and declined, while the US sales were really, I think, the biggest part of your revenues. Given that it remains a small proportion of group revenue, I think you target international revenue to be rather in the 5% to 10% range of sales in the medium term. What is the outlook? How big could really the sales acceleration be, and has anything happened that maybe makes you more cautious on these markets?

Speaker #2: Yes, hi, just a follow-up—maybe on the international sales. I saw that the number was quite lumpy and declined, while the US sales were really, I think, the biggest part of your revenues. Just, I mean, given that it remains a small proportion of group revenue, I think you target international revenue to be rather in the 5% to 10% range of sales in the medium term.

Speaker #2: So, what is the outlook? I mean, how significant could the sales acceleration really be? And, you know, has anything happened that maybe makes you more cautious on these markets?

Chris Fair: No, I think the international marketplace are a great opportunity for us. Just a reminder for the group, the international revenue is calculated differently than domestic revenue. International revenue, we sell to a third party, and the third party would then sell to the local hospital. We do not receive end dollar revenue. It is rather a transitional amount of money. We are registered in 27-plus countries. We have MDR approval. There is a lot of upside in the international market yet to be seen. We have some strategic initiatives internally that we are looking to add focus and effort, and we hope to see that in very short to mid-term to grow that business so that it can be 5% to 10% of our overall revenue. The contribution margins of that business are also very strong to the business. I think that we should see incremental growth.

Speaker #3: No, I think the international marketplace are a great opportunity for us. And also just a reminder for the group, the international revenue is calculated differently than domestic revenue.

Speaker #3: International revenue, we sell to a third party and the third party would then sell to the local hospital. And so we don't receive end dollar revenue.

Speaker #3: It's rather a transitional amount of money. We're registered in 27-plus countries. We have MDR approvals, so there's a lot of upside in the international market yet to be seen.

Speaker #3: We have some strategic initiatives internally that we're looking to add focus and effort to, and we hope to see that in the very short- to mid-term, to grow that business so that it can be 5% to 10% of our overall revenue.

Speaker #3: The contribution margins of that business are also very strong for the business. So I think that we should see incremental growth because it is a distributor-based business, where they're buying the product from us.

Chris Fair: Because it is a distributor-based business where they are buying the product from us, it can be a bit lumpy as you mentioned. We still see tremendous upside in the international marketplace.

Speaker #3: It can be a bit lumpy, as you mentioned, but we still see tremendous upside in the international marketplace.

Laura Pfeifer-Rossi: Okay. Thank you.

Chris Fair: Yeah.

Speaker #2: Okay. Thank you.

Operator: Thank you. I would like to hand back over to Carly Dahmer for webcast questions now.

Speaker #1: Thank you. I would like to hand back over to Carly Dummer for webcast questions now.

Carly Dahmer: Thank you very much. Okay. I will first cover a couple of questions from Tanya from UBS. Similar to the question around surgeon utilization. You indicated 16% surgeon utilization. Can you confirm how many surgeons you are onboarding per month and how you expect this to develop over the remainder of the year? How long does it take for surgeons to start generating sales?

Carly Dummer: Thank you very much. Okay. I will first cover a couple of questions from Tanya from UBS. Similar to the question around surgeon utilization. You indicated 16% surgeon utilization. Can you confirm how many surgeons you are onboarding per month and how you expect this to develop over the remainder of the year? How long does it take for surgeons to start generating sales?

Speaker #6: Thank you very much. Okay. I will first cover a couple of questions from Tanya from UBS. Similar to the question around surgeon utilization, you indicated 16% surgeon utilization.

Speaker #6: Can you confirm how many surgeons you're onboarding per month and how you expect this to develop over the remainder of the year and how long did it take for surgeons to start generating sales?

Chris Fair: Providing all the statistical data is not something we traditionally want to do and provide that. I think that it is good to understand the process of getting a surgeon on board. We see a little bit of difference, right? When we start with a brand-new hospital, it can take somewhere between 6 to 8 months from the time that a surgeon would say, "I would like to use the product," to the time that the hospital allows the product to be sold. The reason being is you have to establish pricing and get on contract and go through VAC committees, et cetera. Once you are through that process and you are approved through the hospital system or you are on a national contract or an IDN contract, then the use becomes pretty free-flowing.

Speaker #3: So you're providing all the statistical data is not something we traditionally want to do and provide that. But I think that it's good to understand the process of getting a surgeon on board and we see a little bit of difference, right?

Speaker #3: So when we start with a brand new hospital, it can take somewhere between 6 to 8 months from the time that a surgeon would say, I'd like to use the product to the time that the hospital allows the product to be sold.

Speaker #3: And the reason is you have to establish pricing and get on contract and go through VAT committees, et cetera, et cetera. But once you're through that process and you're approved through the hospital system or you're on a national contract or an IDN contract, then the use becomes pretty free-flowing.

Chris Fair: The good news is, being in over 600-plus hospitals in the United States and approved, the extremity business can piggyback off that. When we are already on the shelf, we are able to see a quicker pickup in growth. It makes it easier to expand to other surgeons that may not be aware of your technology just yet, but having it available in the hospital. Long answer to a short question. I think that the taxable numbers, we do not normally release. That is the process that a surgeon will go through, and the timing that it takes. Anywhere between four to six months from the time that they agree and they have reviewed the data, they find the right patient population to getting it on the shelf for the hospital to use, tends to be the timeframe.

Speaker #3: The good news is, being in over 600 hospitals in the United States and being approved, the extremity business can piggyback off that.

Speaker #3: And so when we're already on the shelf, we're able to see a quicker pickup and growth. And then it makes it easier to expand to other surgeons that may not be aware of your technology, just yet but having it available in the hospital.

Speaker #3: So you know, long answer to a short question, I think that the tactical numbers we don't normally release, but that's the process that a surgeon will go through and the timing that it takes.

Speaker #3: So anywhere between 4 to 6 months from the time that they agree and they reviewed the data, they find the right patient population, to getting it on the shelf or the hospital to use, that tends to be the timeframe.

Chris Fair: After they start using it, surgeons will traditionally pick a certain indication, use it for that indication, review the results, and then come back and expand after that. It is kind of their cautious approach to approaching clinical evidence in medicine.

Speaker #3: And then after they start using it, surgeons will traditionally pick a certain indication, use it for that indication, review the results, and then come back and expand after that.

Speaker #3: It's kind of their cautious approach to clinical evidence and medicine.

Carly Dahmer: Great. Thank you, Chris. Another couple of questions from Tanya. How did the Medtronic partnership contribute to sales in H1? Is the share of revenues increasing?

Carly Dummer: Great. Thank you, Chris. Another couple of questions from Tanya. How did the Medtronic partnership contribute to sales in H1? Is the share of revenues increasing?

Speaker #6: Great, thank you, Chris. Another couple of questions from Tanya: How did the Medtronic partnership contribute to sales in H1? Is the share of revenues increasing?

Chris Fair: The great news is that our partnership with Medtronic continues to be strong and meaningful. Again, we have not previously, nor will we today talk about the percentage of our revenue, but they are an excellent partner of ours. We continue to grow the business inside the relationship with Medtronic, as well as outside the relationship with Medtronic. As I have said in the past, we want to make sure that we have balance within the system, that we are just not relying on a singular relationship or distribution partner. Also as we grow our extremities business, the percentage of our revenue that is dedicated to spine and invariably our spine relationship with Medtronic becomes a lesser percentage of total revenue. Again, de-risking the business as we continue to grow. The partnership remains strong. We continue to work well together.

Speaker #3: So the great news is that our partnership with Medtronic continues to be strong and meaningful. Again, we have not previously nor we will we today talk about the percentage of our revenue, but they're an excellent partner of ours.

Speaker #3: We continue to grow the business inside the relationship with Medtronic, as well as outside the relationship with Medtronic. As I’ve said in the past, we want to make sure that we have balance within the system, that we’re not just relying on a singular—you know, a singular relationship or distribution partner.

Speaker #3: And so also as we grow our extremities business, the percentage of our revenue that's dedicated to spine and, you know, invariably our spine relationship with Medtronic becomes lesser percentage of total revenue.

Speaker #3: Again, de-risking the business as we continue to grow. So the partnership remains strong, we continue to work well together, but we're also growing the business outside of the Medtronic relationship.

Chris Fair: But we are also growing the business outside of the Medtronic relationship.

Carly Dahmer: Thank you. Similar to the prior question about international sales, what was the reason for the weak Q2 sales? Can you talk about how you think of the international market strategically and if this will become a focus, and how we will accelerate share gains in that space?

Carly Dummer: Thank you. Similar to the prior question about international sales, what was the reason for the weak Q2 sales? Can you talk about how you think of the international market strategically and if this will become a focus, and how we will accelerate share gains in that space?

Speaker #6: Thank you. Similar to the prior question about international sales, what was the reason for the week Q2 sales? Can you talk about how you think of the international market strategically and if this will become a focus and how we will accelerate share gains in that space?

Chris Fair: There were a handful of marketplaces that had some regulatory challenges or shifts. I think more of anything, this is more of a timing of revenue. Again, to Laura's comment earlier, that can be a bit lumpy from time to time, as is distributor-based relationship, not on procedures. I think that from a focus perspective, it certainly is one of our focuses to get that percentage up as far as a total percentage of overall revenue. We have some strategies currently ongoing, renewed focus in this arena. We do believe this will continue to grow in the future. But we do also think that there is some opportunities for improvement from an infrastructure and focus standpoint, and we are taking those measures now.

Speaker #3: So there were a handful of marketplaces that had some regulatory challenges or shifts. I think the more of anything this is more of a timing of revenue again to Laura's comment earlier that can be a bit lumpy from time to time as is distributor-based relationship, not on procedures.

Speaker #3: I think that from a focus perspective, it certainly is one of our focuses to get that percentage up as far as a total percentage of overall revenue.

Speaker #3: We have some strategies currently ongoing renewed focus in this arena. So we do believe this will continue to grow in the future. But we do also think that there's some opportunities for improvement from an infrastructure and focus standpoint and we're taking those measures now.

Carly Dahmer: Great. I am now going to hand back over to the conference line. We have Christophe from Kepler Cheuvreux.

Carly Dummer: Great. I am now going to hand back over to the conference line. We have Christophe from Kepler Cheuvreux.

Speaker #6: Great. I'm now going to hand back over to the conference line. We have Chris Duff from Kepler Chevron.

[Analyst] (Kepler Cheuvreux): Christophe. I just wanted to know if you can provide more granularity on the growth, especially on the growth mix, how much of the H1 growth came from deeper market penetration in existing spine accounts versus neurosurgeon conversions, for instance, and also among MIS, extremity, and trauma, which of these is currently contributing the most to that incremental growth you have delivered?

Speaker #2: Question. I just wanted to know if you can provide more granularity on the growth. Especially on the growth mix, how much of the first half growth came from deeper market penetration in existing spine accounts versus new surgeon conversion, for instance, and also among MIS extremity and trauma which of these is currently contributing the most to that incremental growth you have delivered.

Chris Fair: So, thanks for the question. I think that the overall message here is that we're not dependent upon one of these levers. The level of detail that you've asked in the question, we just don't normally provide. But what I can say is a couple things. The number of hospitals that we're growing into continues to expand both in spine and extremities. So our base gets wider. The number of surgeons that we're onboarding, we're outpacing what we predicted on the extremity side. Also our spine continuously grows on the number of new surgeons that we're bringing into the fold. On top of that, we see existing surgeons expanding their practice. So we are not dependent upon one lever of just getting an additional surgeon to do five more cases the next month.

Speaker #3: So thanks for the question. I think that the overall message here is that we're not dependent upon one of these levers and the level of detail that you've asked in the question, we just don't normally provide.

Speaker #3: But what I can say is a couple of things. The number of hospital growth, the hospitals that we're growing into continues to expand both in spine and extremities.

Speaker #3: So our base gets wider. The number of surgeons that we're onboarding or outpacing what we predicted on the extremity side and also our spine continues to grow on the number of new surgeons that we're bringing into the fold.

Speaker #3: On top of that, we see existing surgeons expanding their practice. So we are not dependent upon one lever of just getting an additional surgeon to do five more cases in the next month.

Chris Fair: We're getting existing customers to expand just from using it in their cervical cases into their lumbar cases. We're getting surgeons to say, "I've got a partner who's never used the product. How do we get that partner to use it?" That helps. Our IDN strategy, our national contract strategy domestically, that's adding brand-new hospital systems that we didn't have access to before. So the question is well-focused, but it also it's coming from different areas, all well-measured and heading in the right direction. So although we don't give away the data, you're on the right track in the sense that we are expanding across all platforms, whether it's new surgeon acquisition, whether it's spine versus extremities. We're expanding across the board.

Speaker #3: We're getting existing customers to expand just from using it in their cervical cases into their lumbar cases. We're getting surgeons to, say, I've got a partner who's never used the product how do we get that partner to use it and that helps.

Speaker #3: Our IDN strategy, our national contract strategy and domestically, that's adding brand new hospital systems that we didn't have access to before. So the question is, well, focused, but it also it's coming from different areas all well measured and heading in the right direction.

Speaker #3: So although we don't give away the data, you're on the right track in the sense that we're expanding across all platforms, whether it's new surgeon acquisition, whether it's spine versus extremities, we're expanding across the board.

[Analyst] (Kepler Cheuvreux): Okay. Thanks. Very clear. And maybe one more on the profitability, if I can, before handing over. On the adjusted EBITDA, so what you have reported in the H1 is already quite close to the full-year target. So I just wanted to know if we should expect further sequential margin expansion in H2, or should we consider that the manufacturing startup and the commercial investment will offset the operating leverage in the second half?

Speaker #2: Okay, thanks. Very clear. And maybe one more on the profitability, if I can, before handing over. On the adjusted EBITDA—so what you have reported in the first half is already quite close to the full-year target.

[Analyst] (Kepler Cheuvreux): wanted to know if we should expect further sequential margin expansion in H2, or should we consider that the manufacturing startup and the commercial investment will offset the operating leverage in the second half?

Speaker #2: So I just wanted to know if we should expect further sequential margin expansion in H2 or should we consider that the manufacturing startup and the commercial investment will offset the operating leverage in the second half?

Daniel Geiger: Well, as I mentioned already before when I answered the question to Laura, I think right now we believe that there will be some dilution, of course, because as said, we are building currently a second production team in the US which will eat into the margin, as you can imagine. But as said, once we have full visibility, which will be around Q3, then we will also give an update there. But it's certainly a positive trend we have seen now in H1, and let's see how this continues.

Speaker #3: Well, as I mentioned already before when I answered the question to Laura, I think right now we believe that there will be some dilution, of course, because as said, we are building currently a second production team in the US, which will eat into the margin as you can imagine.

Speaker #3: But, you know, as I said, I mean, once we have full visibility—which will be around Q3—then we will also give an update there.

Speaker #3: But, you know, it's certainly a positive trend. We have seen now in H1 and let's see how this continues.

[Analyst] (Kepler Cheuvreux): Okay. Thank you.

Speaker #2: Okay. Thank you.

Carly Dahmer: Okay. Next, we have Martin from Baader. First, a comment. Congratulations on the strong performance in H1 2026. Then we've got a few questions here. Could you provide more details on the profitability trends? The gross profit margin increased by 2.1 percentage points, while operating costs as a percentage of revenues decreased by 2.2 percentage points. Was this influenced by raw material prices? What impact did energy prices have, and how did they evolve?

Carly Dummer: Okay. Next, we have Martin from Baader. First, a comment. Congratulations on the strong performance in H1 2026. Then we've got a few questions here. Could you provide more details on the profitability trends? The gross profit margin increased by 2.1 percentage points, while operating costs as a percentage of revenues decreased by 2.2 percentage points. Was this influenced by raw material prices? What impact did energy prices have, and how did they evolve?

Speaker #6: Okay. Next we have Martin from BARDA. First, a comment. Congratulations on the strong performance in H1 2026. And then we've got a few questions here.

Speaker #6: Could you provide more details on the profitability trends? The gross profit margin increased by 2.1 percentage points while operating costs as a percentage of revenues decreased by 2.2 percentage points.

Speaker #6: Was this influenced by raw material prices? What impact did energy prices have and how did they evolve?

Daniel Geiger: Yeah, on the gross profit margin, what we certainly see is now that with the larger scale, we see obviously now also the benefits coming through. Chris also alluded to that. Economies of scale is certainly an important lever for us. What we also see is that now with the US production coming live, we should see a further reduction of transportation costs. We haven't seen that to the full extent right now, but we are now starting to stagger basically also shipments from Europe to the US, given that we have quite some inventory in the US and therefore try to manage that and smooth it as well from a transportation cost perspective. Raw material, I would say, was fairly stable. We haven't really seen that much of a downtrend there, and also energy prices was fairly stable.

Speaker #3: Yeah. I mean, on the gross profit margin, what we certainly see is now that, you know, with the larger scale, we see obviously now also, you know, the benefits coming through.

Speaker #3: So Chris also alluded to that, you know, economies of scale is certainly an important lever for us. What we also see is that, you know, now with, you know, the US production coming live, we should see, you know, further reduction of transportation costs.

Speaker #3: We haven't seen that to the full extent right now, but we are now starting to stagger basically also shipments from Europe to the US given that we have quite some inventory in the US and therefore, you know, try to manage that and smooth it as well from a, you know, transportation cost perspective.

Speaker #3: Raw material, I would say was fairly stable. We haven't really seen that much of a, you know, downtrend there and also energy prices was fairly stable.

Daniel Geiger: We work with certain secured energy prices, and therefore currently we see that as also stable component. Last but not least, I think, in the long run, certainly the labor cost will also help us to further bring that down. Don't forget, majority of the costs are really the calcium phosphate going in there and the syringes. Therefore, we will work on that end to further optimize the procurement in order to further get benefits. It's all going into the right direction. We have just started cost improvement programs in procurement and production. We continue to now benefit also from the data and the visibility we get by production batch. This is part of the digitalization we did of the production of the supply chain, and this now starts to pay off. We are now able to focus on the cost efficiency programs.

Speaker #3: I mean, we work, you know, with certain secured energy prices and therefore currently we see that, you know, as also stable component. And last but not least, I think, you know, in the long run, certainly the labor cost will also help us to further bring that down, but don't forget majority of the costs are really the calcium phosphate going in there and the syringes and, you know, therefore we will work on that end to further optimize the procurement in order to further get benefits.

Speaker #3: But it's all going into the right direction. We have just started cost improvement programs in procurement and production and continue to now benefit also from the data and the visibility we get by production batch.

Speaker #3: So this is part of the digitization we did of the production and the supply chain and this now starts to pay off. So we are now able to focus on cost efficiency programs.

Carly Dahmer: Great. What are the CapEx plans for H2 2026 and the subsequent years?

Carly Dummer: Great. What are the CapEx plans for H2 2026 and the subsequent years?

Speaker #6: Great. What are the capital expenditure plans for H2 2026 and the subsequent years?

Daniel Geiger: We said that we're going to invest CHF 11 to 12 million in the US, about CHF 2 to 3 million in the Netherlands, and then about CHF 1 million IT applications, right? We have spent now about half of that, a little bit less. We will continue to spend in the US specifically, but also in the Netherlands, because both locations are super strategic for us. From that end, we will continue to see some pressure on the cash, if that's the question. We have, as I said, this backstop facility, which supports us if needed. We always have looked at the cash from that perspective that we will see in Q3 a low point, and then we'll see a catch-up in Q4 along the lines of our operating cash flow modeling, right?

Speaker #3: I mean, we said that we're going to invest 11 to 12 in the US about 2 to 3 in the Netherlands and then about a million IT applications, right?

Speaker #3: We have spent now about half of that, a little bit less. So we will continue to spend in the US specifically, but also in the Netherlands.

Speaker #3: Because both locations are super strategic for us, and, you know, from that end, we will continue to see some pressure on the cash, if that's the question.

Speaker #3: You know, we have, as said, this backstop facility which supports us if needed. We have always looked at cash from that perspective—that we will see a low point in Q3, and then we'll see a catch-up in Q4, along the lines of our operating cash flow modeling, right?

Daniel Geiger: What I can say to the full audience here is that we have to implement, a year ago, a 13-week cash flow model and a 15-month cash flow model. We know exactly where the cash is going, how we are going to hedge it from an ethics perspective, and how we manage it. What we see currently from a trend perspective is all planned. There is no surprise right now, and everybody is focused and calm in their execution. From that end, that is fine. In terms of 2027 and beyond, it is somewhere in the range of 2 to 3 million, but certainly not big CapEx. Do not forget, this is not an expensive business from a capital point of view.

Speaker #3: And I mean, what I can say to the full audience here is that, you know, we have implemented a year ago a 13-week cash flow model and the 15-month cash flow model.

Speaker #3: So we know exactly where the cash is going, how we're going to hedge it from an ethics perspective, and how we manage it. So, all that we see currently from a trend perspective is all planned.

Speaker #3: So there's no surprise right now. And, you know, everybody's focused and calm in their execution. And from that end, that's fine. In terms of 27 and beyond, you know, it's somewhere in the range of 2 to 3 million but certainly not big capital expenditure.

Speaker #3: Don't forget, this is not an expensive business from a capital point of view.

Carly Dahmer: Thank you. You mentioned capacity expansion in the Netherlands and the new facility in the US. What sales levels are anticipated once these are fully operational?

Carly Dummer: Thank you. You mentioned capacity expansion in the Netherlands and the new facility in the US. What sales levels are anticipated once these are fully operational?

Speaker #6: Thank you. You mentioned capacity expansion in the Netherlands and the new facility in the US. What sales are anticipated once these sales levels are anticipated once these are fully operational?

Chris Fair: Well, as we have already given guidance on midterm of $300 to $330 million, and so that right now, until we look at adjusting guidance, as Daniel Geiger mentioned in Q3, those will be the levels that we are putting out there. I think it is really important to understand the strategic value of these different arenas for manufacturing. Number 1, it provides bandwidth for growth. Number 2, it provides localized inventory production to help be closer to adjusting time inventory system in the sense that we are providing inventory and not having as much networking capital tied up. I think it also allows for new product and innovation. If we have to have places to develop all the products that we have in the pipeline, we have to have a place to make them.

Speaker #3: Well, as we've already given guidance on midterm of 300 to 330 million dollars. And so that right now until we look at adjusting guidance as Daniel mentioned in the third quarter, those will be the levels that we're putting out there.

Speaker #3: I think it’s really important to understand the strategic value of these different arenas for manufacturing. Number one, it provides bandwidth for growth. Number two, it provides localized inventory production to help, you know, be closer to a just-in-time inventory system in the sense that we’re providing inventory and not having as much net working capital tied up.

Speaker #3: I think it also allows for new products and innovation. If we have to have places to develop the products that we have in the pipeline, we have to have a place to make them.

Chris Fair: For all those reasons, and also getting operational leverage and, as Daniel Geiger mentioned, with some of the programs we have ongoing currently. For all these reasons, this investment in the infrastructure is so important for setting the foundation for this next tier of growth that we are going to experience.

Speaker #3: So for all those reasons and then also getting operational leverage and as Daniel mentioned with some of the programs we have ongoing currently, for all these reasons, this investment in the infrastructure is so important for setting the foundation for this next tier of growth that we're going to experience.

Carly Dahmer: Thank you, Chris. We actually have a similar question from Jose from Chopard. For the H2 2026, what proportion of total production do you expect to allocate to the US facility versus the Netherlands facility?

Carly Dummer: Thank you, Chris. We actually have a similar question from Jose from Chopard. For the H2 2026, what proportion of total production do you expect to allocate to the US facility versus the Netherlands facility?

Speaker #6: Thank you, Chris. We actually have a similar question from Yosef from Chopard. For the second half of 2026, what proportion of total production do you expect to allocate to the US facility versus the Netherlands facility?

Chris Fair: Yeah. From a percentage perspective, we are not going to push out. Again, we are just bringing online a manufacturing facility here in the US. Products that are sold in 2026 will, for the most part, be sold from products that were manufactured in the Netherlands. As we continue to grow, we also, again, look at product development and where the right location to produce those products. We are going to balance out our manufacturing strategy to make sure we have capacity, we de-risk the business, look at the cost and tax implications as well.

Speaker #5: Yeah, from a percentage perspective, we're not going to push out. You know, again, we're just bringing online the manufacturing facility here in the U.S.

Speaker #5: Products that are sold in 2026 will for the most part be sold from products that were manufactured in the Netherlands. As we continue to grow, we also again look at product development and where the right location to produce those products.

Speaker #5: We're going to balance out our manufacturing strategy to make sure we have capacity. We've de-risked the business, look at, you know, the cost and tax implications as well.

Chris Fair: From a percentage perspective, I am just happy that getting another facility online from a de-risking of the business is really, really important, number one, in the sense that we now have some capacity built in because we have been growing at such a high cadence and really pressing and pushing the operations in the pipeline, and just maximizing all of that. So now this provides a little bit of breathing room, so now we have more capacity for new product development. So from my perspective, that is the greatest strategic advantage of these two arenas.

Speaker #5: But, you know, from a percentage perspective, I'm just happy that, you know, getting another facility online from a de-risking of the business is really, really important.

Speaker #5: Number one, in the sense that we now have some capacity built in because we've been growing at such a high cadence, really pressing and pushing the operations and the pipeline, and just maximizing all of that.

Speaker #5: And so now this provides a little bit of breathing room, so now we have more capacity for new product development. So, from my perspective, that's the greatest strategic advantage of these two arenas.

Carly Dahmer: Thank you. Final question from Martin. Is there a version of MagnetOs available for robot-assisted surgery?

Carly Dummer: Thank you. Final question from Martin. Is there a version of MagnetOs available for robot-assisted surgery?

Speaker #6: Thank you. And final question from Martin: Is there a version of Magnetross available for robot-assisted surgery?

Chris Fair: It is funny you say that. Actually, when we were developing the MIS, there was a fair amount of interaction with several partners of looking at this and being used with different robotic platforms. The technology itself can be used in cannulas and has been used on cannulas in different robotic platforms. Robotics is not an area that we are going to get into, but we certainly have reached out and worked with partners, including Medtronic, on their robotic platforms to make sure that our product is compliant with their delivery tools.

Speaker #5: You know, it's funny you say that. Actually, what we were developing the MIS, there was a fair amount of interaction with several partners of looking at this and being used with different robotic platforms.

Speaker #5: And so the technology itself can be used in cannulas and has been used on cannulas and different robotic platforms. Robotics is not an area that we're going to get into, but we certainly have reached out and worked with partners, including Medtronic, on their robotic platforms to make sure that our product is compliant with their delivery tools.

Carly Dahmer: Great. Thank you. Next up, Rene from Octavian. Given the strong clinical evidence, how do you see the dynamics of MagnetOs competing to the more expensive growth factors segment, and is there an opportunity to raise prices going forward?

Carly Dummer: Great. Thank you. Next up, Rene from Octavian. Given the strong clinical evidence, how do you see the dynamics of MagnetOs competing to the more expensive growth factors segment, and is there an opportunity to raise prices going forward?

Speaker #6: Great, thank you. Next up, Renee from Octavian. Given the strong clinical evidence, how do you see the dynamics of MagnetOs competing with the more expensive growth factors segment?

Speaker #6: And is there an opportunity to raise prices going forward?

Chris Fair: Well, pricing is an interesting thing. A lot of the conversations that we have and I have with different hospital systems, what they are realizing is that with our clinical evidence from a cost-benefit analysis versus other advanced biologics, the best bang for the buck, as it were, they are seeing the value proposition that we provide. Our pricing strategy has been straightforward in the event that if you are a cost-conscious buyer, you can have access to our core technology through the granules at a lower price point. If you wish to have something that is more advanced, i.e., an MIS delivery mechanism, we will take price premiums that way. What this allows is based on the different types of buyers that we have and also the different settings, as we have different settings between hospitals and surgery centers, et cetera. Pricing does matter because the reimbursement landscape is different.

Speaker #5: So, you know, pricing is an interesting thing. You know, a lot of the conversations that we have and I have with different hospital systems what they're realizing is that with our clinical evidence from a cost-benefit analysis, versus advanced other advanced biologics, you know, the best bang for the buck, as it were, they're seeing the value proposition that we provide.

Speaker #5: Our pricing strategy has been straightforward in the event that if you are a cost-conscious buyer, you can have access to our core technology through the granules at a lower price point.

Chris Fair: If you wish to have something that is more advanced, i.e., an MIS delivery mechanism, we will take price premiums that way. What this allows is based on the different types of buyers that we have and also the different settings, as we have different settings between hospitals and surgery centers, et cetera. Pricing does matter because the reimbursement landscape is different.

Speaker #5: If you wish to have something that's more advanced, i.e., an MIS delivery mechanism, we'll take price premiums that way. What this allows is based on the different types of buyers that we have and also the different settings as we have different settings between hospitals and surgery centers, etc.

Speaker #5: Pricing does matter because the reimbursement landscape is different. And so, we're very thoughtful in our pricing strategy by product line to ensure that the base technology can still be accessed at a lower-cost procedure.

Chris Fair: We are very thoughtful in our pricing strategy by product line to ensure that the base technology can still be accessed in a lower cost procedure. That is how we have priced the products. Traditionally, price increases, once you are in a contract, especially with hospital systems, those contracts run between one, two, and three years domestically, and getting a price increase is not something that is easy to do. Normally, a price increase comes with new technologies or new platforms or new features and benefits you are introducing into the technology. But that has been our pricing strategy from the get-go, and it has worked so well.

Speaker #5: And so that's how we've priced the products. Traditionally, price increases once you're in a contract, especially with hospital systems, those contracts run between one, two, and three years.

Speaker #5: Domestically. And so getting a price increase is not something that's easy to do. Normally, price increase comes with new technologies or new platforms or new features and benefits you're introducing into the technology.

Speaker #5: But that's been our pricing strategy. From the get-go, and it's been very, you know, it's been it's worked so well.

Carly Dahmer: Great. Related question from Sergei at Octavian. Once the two manufacturing sites are up and running and your MagnetOs MIS Gen 2 is launched, is it right to assume that growth margins will be able to reach 90%?

Carly Dummer: Great. Related question from Sergei at Octavian. Once the two manufacturing sites are up and running and your MagnetOs MIS Gen 2 is launched, is it right to assume that growth margins will be able to reach 90%?

Speaker #6: Great. Related question from Sergey at Octavian. Once the two manufacturing sites are up and running and your Magnetoss MIS Gen2 is launched, is it right to assume that growth margins will be able to reach 90%?

Daniel Geiger: Yeah. I said, unadjusted or adjusted, basically we are, for Terrace, we are at 90%. From that end, I said we will continue to further optimize the unit cost. The more we scale, the more we will be able to bring down the fixed cost per unit. Therefore, it might well be that we will further be able to increase it. But as I said, this is at the later stage where we are going to comment on that if we see it then coming through. But the expectation is not totally incorrect.

Speaker #5: Yeah, I mean, as I said, I mean, on the jobs that—or jobs that—basically, we are, for tariffs, we are at 90%. So, you know, from that end, I said we will continue to further optimize the unit cost and, you know, the more we scale, the more we will be able to bring down the fixed cost per unit and, therefore, it might well be that we will further be able to increase it. But I said, I mean, this is at the latest stage where we're going to comment on that if we see it then coming through.

Speaker #5: But the expectation is not totally incorrect.

Carly Dahmer: Great. I think this question has partially been answered. Rene from Octavian. In your press release, you mentioned market share gains across all segments. Can you please elaborate on which areas you currently see the biggest momentum and where you see the biggest opportunities going forward?

Carly Dummer: Great. I think this question has partially been answered. Rene from Octavian. In your press release, you mentioned market share gains across all segments. Can you please elaborate on which areas you currently see the biggest momentum and where you see the biggest opportunities going forward?

Speaker #6: Great. I think this question has been partially answered, Renée from Octavian. In your press release, you mentioned market share gains across all segments. Can you please elaborate on which areas you currently see the biggest momentum and where you see the biggest opportunities going forward?

Chris Fair: Sure. I think that from a market share perspective, we are seeing growth, as I mentioned earlier, across the board from existing customers expanding the new procedures. If they started in cervical, they might be moving into the lumbar area, et cetera. But we are seeing significant pickup in the foot and ankle based on our effort, our focused effort there, and also as our early expansion efforts in the trauma indications. As we have laid out before, our strategy is to start with a small group and a focused arena, ensure we have the right product for the right procedure, that we have the right study allocated for that.

Speaker #5: So, sure, I think that from a market share perspective, we’re seeing growth—as I mentioned earlier—across the board, from existing customers expanding into new procedures.

Speaker #5: If they started in cervical, they might be moving into the lumbar area, etc. But we are seeing significant pickup in the foot and ankle based on our effort, our focus effort there.

Speaker #5: And also as our early expansion efforts in the trauma indications. And so as we've laid out before, our strategy is to start with a small group and a focused arena to ensure we have the right product for the right procedure and that we have the right study out, you know, allocated for that.

Chris Fair: What we have been seeing in the H1 of this year, as we started going out into the trauma indications, we are seeing great feedback because surgeons now have 6, 8, 10-week, 12-week data coming back and saying, "Holy cow, this is working quite well. This is better than what I used to use." That is with a focus group of surgeons. We are seeing greater penetration, but again, the reaction to new marketplaces like trauma or foot and ankle is similar to what we saw in spine, and that is very, very encouraging as we continue to expand into those communities.

Speaker #5: And so what we've been seeing in the first half of this year is we started going out into the trauma indications. We're seeing great feedback because surgeons now have 6, 8, 10, 12-week data.

Speaker #5: Coming back and saying, holy cow, this is working quite well. This is better than what I used to use. And so that's what the focus group of surgeons.

Speaker #5: So we are seeing greater penetration, but again, the reaction to new marketplaces like trauma or foot and ankle is similar to what we saw in spine.

Speaker #5: And that's very, very encouraging as we continue to expand into those communities.

Carly Dahmer: Great. I have a couple more questions from Tanya from UBS. Can you update or provide some additional color on Q2 exit rates? How has the Q3 performance been so far?

Carly Dummer: Great. I have a couple more questions from Tanya from UBS. Can you update or provide some additional color on Q2 exit rates? How has the Q3 performance been so far?

Speaker #6: Great. I have a couple more questions from Tanya from UBS. Can you update or provide some additional callouts on Q2 exit rates? How has the Q3 performance been so far?

Chris Fair: Well, on Q2, again, when we look at the numbers, we saw a significant increase over Q1. I believe it was 42.9 and 49, if I am correct. It is a pretty significant step up. Again, when we start looking at Q3, we are not going to comment on that until the numbers are in. But as we have discussed in the past, there is a cyclical nature to our business in the sense that a good portion of the business comes in the H2, and the reason being is, in the US healthcare system, Q4 tends to be the highest quarter for procedure volumes. With a high exposure of about 95% of our revenue coming from the US, you would see that impact. That is where we see the delta between the H1 and the H2. We do not see that changing.

Speaker #5: Yeah, so on Q2, again, when we look at the numbers, we saw a significant increase over Q1. I believe it was 42.9 and 49, if I'm correct.

Speaker #5: And so, it's a pretty significant step up. Again, when we start looking at, you know, Q3, we're not going to comment on that until the numbers are in.

Speaker #5: But as we've discussed in the past, there is a cyclical nature to our business in the sense that, you know, a good portion of the business comes in the second half.

Speaker #5: And the reason being is, in the U.S. healthcare system, Q4 tends to be the highest quarter for procedure volumes. And with a high exposure—about 95% of our revenue coming from the U.S.—you would see that impact.

Speaker #5: And so that's where we see the delta between the first half and the second half. We don't see that changing the procedure volumes tend to be that way.

Chris Fair: The procedure volumes tend to be that way, have been that way, and most med tech companies with a high US exposure will also experience that. That is what we have seen so far, but no, we had a great significant step-up from Q1 to Q2. As we saw on the revenue line, continued growth, continued adoption, and that seems to be going forward.

Speaker #5: It has been that way, and most med tech companies with a high U.S. exposure will also experience that. So that's what we've seen so far.

Speaker #5: But no, we've had a great, significant step up from Q1 to Q2. As we saw in the revenue line: continued growth, continued adoption, and that seems to be going forward.

Carly Dahmer: Great, and final question from Tanya. Daniel, you've spoken to most of this. For CapEx, what remaining investments are outstanding for the US facility and the Netherlands expansions? Do you expect a higher CapEx number in the H2?

Carly Dummer: Great, and final question from Tanya. Daniel, you've spoken to most of this. For CapEx, what remaining investments are outstanding for the US facility and the Netherlands expansions? Do you expect a higher CapEx number in the H2?

Speaker #6: Great. And final question from Tanya. I think Daniel has spoken to most of this. For CapEx, what remaining investments are outstanding for the U.S.?

Speaker #6: facility and the Netherlands expansions? Do you expect a higher CapEx number in the second half?

Daniel Geiger: No. About the same, probably a little bit more, but as I said, max, we're going to spend CHF 15 to 16 million. You can do the math if you look at our fixed asset table, but it's about half of what we spent so far. That said, all well planned through and nothing to worry about.

Speaker #5: No, about the same. Probably a little bit more, but I said max we're going to spend 15 to 60 million. You can do the math if you look at our fixed asset table.

Speaker #5: But you know, it's about half of what we've spent so far. And as I said, all well planned through, and nothing to worry about.

Carly Dahmer: Great. One question from Andreas from Alpha Capital. Could you provide a more precise indication of the expected start date of production in the US?

Carly Dummer: Great. One question from Andreas from Alpha Capital. Could you provide a more precise indication of the expected start date of production in the US?

Speaker #6: Great. One question from Andreas from Alpha Capital: Could you provide a more precise indication of the expected start date of production in the U.S.?

Chris Fair: No, at this point in time, we're comfortable in talking about the H2 of this year, is what we've talked about in the past, so no new indication there. Everything seems to be on track and online from an office perspective. We've been able to move our offices in, and production is on track and moving according to plan. So, no surprises there.

Speaker #5: No, at this point in time, we're comfortable in talking about the second half of this year is what we've talked about in the past.

Speaker #5: So, no new indication there. Everything seems to be on track and online from an office perspective. We've been able to move our offices in, and production is on track and moving according to plan.

Speaker #5: So no surprises there.

Carly Dahmer: Thank you. Henrietta from AWP. Do I understand correctly that sales growth was volume driven and not price driven?

Carly Dummer: Thank you. Henrietta from AWP. Do I understand correctly that sales growth was volume driven and not price driven?

Speaker #6: Thank you. Henrietta from AWP. Do I understand correctly that sales growth was volume-driven and not price-driven?

Chris Fair: Correct.

Speaker #5: Correct.

Carly Dahmer: Peter from One Investments. Did the CMS Medicare Inpatient Prospective Payment System review recently released provide any reimbursement news for Kuros? Is a differentiated reimbursement outcome something you target with the results from Kuros primary research program in any of the focused therapeutic areas?

Speaker #6: Easy. Peter from One Investments. Did the CMS Medicare Inpatient Prospective Payment System review recently released provide any reimbursement news for CUROS? Is a differentiated reimbursement outcome something you target with the results from the CUROS primary research program in any of the focus therapeutic areas?

Carly Dummer: Peter from One Investments. Did the CMS Medicare Inpatient Prospective Payment System review recently released provide any reimbursement news for Kuros? Is a differentiated reimbursement outcome something you target with the results from Kuros primary research program in any of the focused therapeutic areas?

Chris Fair: Certainly, the answer to the first question is no, it didn't affect anything that we get reimbursed for because we come under a DRG. Some of those were related to specific procedures that we don't participate in. But to the second question, when we do product development, are we targeting reimbursement opportunities? I think it's always part of the analysis when we look at going into new market spaces or new product opportunities is what's the reimbursement landscape? Is there an opportunity to have unique identifiers or unique reimbursement codes attached to your technology? And having done this in my career over several times, that can be a blessing and could also be a curse, because sometimes, not having the reimbursement on the front end will slow the revenue ramp, while you try to work through the reimbursement landscape to get your specific code.

Speaker #5: So certainly, you know, the answer to the first question is no—it didn't affect anything that we get reimbursed for, because we come under a DRG.

Speaker #5: Some of those were related to specific procedures that we don't participate in. And so, but to the second question, when we do product development, are we targeting reimbursement opportunities?

Speaker #5: I think it's always part of the analysis when we look at going into new market spaces or new product opportunities—what's the reimbursement landscape?

Speaker #5: Is there an opportunity to have unique identifiers or unique reimbursement codes attached to your technology? And having done this in my career several times, that can be a blessing and it could also be a curse.

Speaker #5: Because sometimes, not having the reimbursement on the front end will slow the revenue ramp. But, you know, while you try to work through the reimbursement landscape to get your specific code, sometimes it works, sometimes it doesn't.

Chris Fair: Sometimes it works, sometimes it doesn't. Also making sure that it lines up with the procedures and your marketing clearances. The reimbursement landscape is a tricky wicket, as they say. For us here and the procedures that we currently attach ourselves to, we fall under a standard DRG, so there's no unique reimbursement. We don't have to have a massive reimbursement staff trying to help with pre-authorizations or anything else to that nature. But we do take it into consideration when looking at new product opportunities, whether it's organic or inorganic and what that reimbursement landscape is.

Speaker #5: And also making sure that it lines up with the procedures and your marketing clearances. So the reimbursement landscape is a tricky wicket. As they say, for us here in the procedures that we currently attach ourselves to, we fall under a standard DRG.

Speaker #5: So there's no unique reimbursement, so we don't have to have a massive reimbursement staff trying to help with pre-authorizations or anything else of that nature.

Speaker #5: But we do take it into consideration when looking at new product opportunities, whether it's organic or inorganic, and what that reimbursement landscape is.

Carly Dahmer: Great. With 5 minutes left, we have a group of questions from Andrew from Goodbody. After years of accelerating absolute growth for the first time, net revenue declined slightly this quarter despite a much bigger sales organization. Have you reached peak absolute growth, or do you think this can re-accelerate?

Carly Dummer: Great. With 5 minutes left, we have a group of questions from Andrew from Goodbody. After years of accelerating absolute growth for the first time, net revenue declined slightly this quarter despite a much bigger sales organization. Have you reached peak absolute growth, or do you think this can re-accelerate?

Speaker #6: Great. With five minutes left, we have a group of questions from Andrew from GoodArt. After years of accelerating absolute growth, for the first time net revenue declined slightly this quarter, despite a much bigger sales organization.

Speaker #6: Have you reached peak absolute growth, or do you think this can re-accelerate?

Chris Fair: Yeah, I would have to look at the numbers, but I do not see that within the numbers. We went from Q1 to Q2 was a relatively even money. We had a massive Q4. I am sorry, from Q4 to Q1 of this year, that was relatively even. Normally, the first quarter is a pullback after the fourth quarter. The second quarter was a high growth over the first quarter. We continue to grow from the sales feet on the street and continue to expand into new market opportunities like extremities. No, I still think absolute growth is trending in the right direction. Again, 45% growth, and I would also say, looking at where we are as a business compared to our competitive companies out there is not a company that is growing at this cadence, this rate, and this absolute CHF dollar revenue at a profitable piece as well.

Chris Fair: Yeah, I would have to look at the numbers, but I do not see that within the numbers. We went from Q1 to Q2 was a relatively even money. We had a massive Q4. I am sorry, from Q4 to Q1 of this year, that was relatively even. Normally, the Q1 is a pullback after the Q4. The Q2 was a high growth over the Q1. We continue to grow from the sales feet on the street and continue to expand into new market opportunities like extremities. No, I still think absolute growth is trending in the right direction. Again, 45% growth, and I would also say, looking at where we are as a business compared to our competitive companies out there is not a company that is growing at this cadence, this rate, and this absolute CHF dollar revenue at a profitable piece as well.

Speaker #5: Yeah, I don't know if I'd have to look at the numbers, but I don't see that within the numbers. I mean, we went from a, you know, from Q1 to Q2 was a relatively even money.

Speaker #5: So we had a massive Q4, I'm sorry, from Q4 to Q1 of this year. That was relatively even. Normally the first quarter is a pullback after the fourth quarter.

Speaker #5: The second quarter was a high growth over the first quarter. We continue to grow from a sales feet on the street and continue to expand into new market opportunities, like extremities.

Speaker #5: So, no, I still think absolute growth is trending in the right direction—again, 45% growth. And I would also say, looking at where we are as a business compared to our competitive market and competitive companies out there, there's not a company that's growing at this cadence, this rate, and this absolute dollar revenue at a profitable pace as well.

Chris Fair: I think that we still see that growth profile continuing. Again, by broadening our base and getting into extremities, albeit at a lower price point per procedure, is important for us strategically from, again, de-risking the business, growing from a wider platform, and improving profitability. This also allows us for new product opportunities as we prepare for things like getting into a new marketplace, such as the cement space or the bone and void filler space. I think that that is also something to take into consideration.

Speaker #5: So I think that we still see that growth profile continuing. And again, broadening our base and getting into extremities, albeit at a lower price point per procedure, is important for us strategically from, again, de-risking the business, growing from a wider platform, and improving profitability.

Speaker #5: This also allows us for new product opportunities as we prepare for things like getting into a new marketplace such as the cement space or the Bowden void filler space.

Speaker #5: And so, I think that's also something to take into consideration.

Carly Dahmer: Great. I think you spoke a little bit to this already, Chris. Growth in spine surgeons that are using MagnetOs has outstripped revenue growth for the average surgeon is using slightly less MagnetOs. Is this just due to recent surgeon acquisition and the fact they are not fully ramped, or because you targeted higher volume surgeons first or another reason? How much scope is there for the current surgeons to increase their own volume?

Carly Dummer: Great. I think you spoke a little bit to this already, Chris. Growth in spine surgeons that are using MagnetOs has outstripped revenue growth for the average surgeon is using slightly less MagnetOs. Is this just due to recent surgeon acquisition and the fact they are not fully ramped, or because you targeted higher volume surgeons first or another reason? How much scope is there for the current surgeons to increase their own volume?

Speaker #6: Great. I think you spoke a little bit to this already, Chris. Growth in spine surgeons that are using MagnetOs has outstripped revenue growth for the average surgeon who's using slightly less MagnetOs.

Speaker #6: Is this just due to recent surgeon acquisition and the fact they're not fully ramped, or because you targeted higher-volume surgeons first, or is there another reason?

Speaker #6: How much scope is there for the current surgeons to increase their own volumes?

Chris Fair: Great question. Surgeon penetration by surgeon is something we track internally. I think you can think about it this way. As we continue to add new surgeons to the mix as they do their first cases, they are also waiting. You end up having this stacked surgeon of, hey, they did two or three cases, they want to wait to see the results of that before they do 10 cases a month or 20 cases, whatever it is going to be. As you are adding surgeons, you are also expanding your surgeons that you currently work with. It can get lumpy from time to time, but directionally correct. We are adding to the number of surgeons that are using the product, and we are expanding the foundation within each one of those surgeons. I think that both of those are moving in the right direction.

Speaker #5: Great question. Surgeon penetration by surgeon is something we track internally. But I think you could think about it this way: as we continue to add new surgeons to the mix, as they do their first cases, they're also waiting.

Speaker #5: And so you end up having this stacked surgeon of, hey, they did two or three cases. They want to wait to see the results of that before they do 10 cases a month or 20 cases, whatever it's going to be.

Speaker #5: And so, as you're adding surgeons, you're also expanding your surgeons that you currently work with. And so, it can get lumpy from time to time, but directionally, we're adding to the number of surgeons that are using the product, and we're expanding the foundation within each one of those surgeons.

Speaker #5: So I think that both of those are moving in the right direction from a timing perspective. It can get a little bit lumpy from time to time, but all are moving directionally correct.

Chris Fair: From a timing perspective, it can get a little bit lumpy from time to time, but all moving directionally correct.

Carly Dahmer: Great. We have 2 minutes, so we will try and get through all of these questions. Stripping the data from the charts, it looks like sales commissions looked as if they increased to 42% of sales in H1. What was driving this increase, and where do you see it trending in the next 24 months?

Carly Dummer: Great. We have 2 minutes, so we will try and get through all of these questions. Stripping the data from the charts, it looks like sales commissions looked as if they increased to 42% of sales in H1. What was driving this increase, and where do you see it trending in the next 24 months?

Speaker #6: Great. We have two minutes, so I will try to get through all of these questions. Stripping the data from the charts, it looks like sales commissions increased to 42% of sales in H1.

Speaker #6: What was driving this increase and where do you see it trending in the next 24 months?

Chris Fair: From a commission perspective, we think that that line will remain stable, if not slightly downward. I think it is something that we have talked about in the past that, commissions, you have to be cautious with messing with commissions with an independent sales network. I think that when we start looking at the overall cost of delivering the product and profitability compared to other orthopedic companies with a large exposure to US revenue, which is all 1099 and commission-based, we are probably one of the best companies, if not the best within the orthopedic sector relative to this metric. We continue to manage it, and we continue to improve upon it.

Speaker #5: Yeah, so from a commission perspective, we think that that line will remain stable, if not slightly downward, but I think that I think it's something that we've talked about in the past that, you know, commissions, you have to be cautious with messing with commissions, with an independent sales network.

Speaker #5: And I think that when we start looking at the overall cost of delivering the product and profitability compared to other orthopedic companies, with a large exposure to U.S. revenue—which is all 1099 and commission-based—we're probably one of the best companies in, if not the best within, the orthopedic sector relative to this metric.

Speaker #5: And so we continue to manage it and we continue to improve upon it. But as we continue to scale, the cost of management and the number of people managing it will pick up sales efficiencies there, which will drive down the overall commission structure, which does account for variable comps for W-2 staff.

Chris Fair: But as we continue to scale, the cost of management and the number of people managing it will pick up sales efficiencies there, which will drive down the overall commission structure, which does account for variable comps for W2 staff.

Carly Dahmer: Great.

Carly Dummer: Great.

Chris Fair: Yeah.

Carly Dahmer: We are at time, so I will end there and hand over to Chris for any final closing remarks.

Carly Dummer: We are at time, so I will end there and hand over to Chris for any final closing remarks.

Speaker #6: Great. We are at time, so I will end that and hand over to Chris for any final closing remarks.

Chris Fair: Thank you, Carly. Again, I want to thank each of you for attending this webcast, being a supporter of the company and our journey. We are set up for a tremendous amount of success in the future. But it is also important to look back in the journey we have been on, not just the first half of this year, but certainly during my time and Daniel's time here. This company has transformed. And we are in a transition year, but we continue to outpace the growth in the industry. We continue to provide great products to the clinicians and the patients that we serve. And we have such a bright future ahead of us with all kinds of operational leverage and profitability to come. So with that, I want to say thank you for attending and thank you for your continuous support.

Speaker #5: Thank you, Carly. Again, I want to thank each of you for attending this webcast and for being a supporter of the company and our journey. We are set up for a tremendous amount of success in the future, but it’s also important to look back on the journey we’ve been on—not just in the first half of this year, but certainly during my time and Daniel’s time here. This company has transformed.

Speaker #5: And we are in a transition year, but we continue to outpace the growth in the industry. We continue to provide great products to the clinicians and the patients that we serve.

Speaker #5: And we have such a bright future ahead of us with all kinds of operational leverage and profitability to come. So with that, I want to say thank you for attending.

Browse all earnings call transcripts

Q2 2026 Kuros Biosciences AG Earnings Call

Request TrialDemo

Kuros Biosciences

Earnings